Immatics Biotechnologies

Latest Headlines

Latest Headlines

Immatics' kidney cancer vaccine extends lives in trials

Renal cell carcinoma patients lived longer when they developed responses to peptides in IMA901, Immatics' multipeptide therapeutic vaccine for kidney cancer, according to a new study published in Nature Medicine.

Immatics starts late-stage cancer vaccine study

Germany's Immatics Biotechnologies says its vaccinated the first first patients in a Phase III study IMA901, the company's lead cancer vaccine for the treatment of renal cell carcinoma. Release